Rethinking treatment paradigms for the deployment of SARS-CoV-2 antiviral drugs on the shifting landscape of new variants.

Hentzien, Maxime; Owen, Andrew; Strub-Wourgaft, Nathalie; Pérez-Casas, Carmen; Trøseid, Marius; Calmy, Alexandra

Hentzien, Maxime; Owen, Andrew; Strub-Wourgaft, Nathalie; Pérez-Casas, Carmen; Trøseid, Marius; Calmy, Alexandra.

Afiliación

Hentzien M; HIV/AIDS Unit, Infectious Diseases Division, Geneva University Hospitals, Geneva, Switzerland.
Owen A; Centre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool, Liverpool, United Kingdom.
Strub-Wourgaft N; COVID Response and Pandemic Preparedness Director, Drugs for Neglected Diseases Initiative (DNDi), Geneva, Switzerland.
Pérez-Casas C; Strategy, Unitaid, Geneva, Switzerland.
Trøseid M; Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Oslo, Norway.
Calmy A; HIV/AIDS Unit, Infectious Diseases Division, Geneva University Hospitals, Geneva, Switzerland.

Front Microbiol ; 13: 998287, 2022.

Article en En | MEDLINE | ID: mdl-36312942

Palabras clave

COVID-19; direct-acting antivirals; immunocompromised; monoclonal antibodies; omicron; resistance; variant emergence; variants

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Microbiol Año: 2022 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google